NeOnc's Most Challenging Test Yet: Compassionate-Use Update Puts NEO100's Potential in FocusNewsfile Corp · Oct 16, 2026
NeOnc's Boldest Test Yet: Child's Early Improvement Puts NEO100 in the Spotlight with Compassionate-Use MilestoneGlobeNewsWire · Oct 16, 2026
NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu DhabiGlobeNewsWire · Oct 16, 2026
NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital PathologyBusiness Wire · Oct 15, 2026
NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026GuruFocus · Oct 14, 2026
NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026Business Wire · Oct 14, 2026NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 28, 2026 | $0.03 | $0.05 | Beat |
| Apr 28, 2026 | $0.01 | $0.01 | Beat |
| Feb 17, 2026 | $0.04 | $0.06 | Beat |
| Oct 28, 2025 | $0.02 | $0.03 | Beat |
| Jul 29, 2025 | $0.03 | $0.03 | Beat |
| Apr 29, 2025 | -$0.02 | -$0.08 | Miss |